These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

447 related items for PubMed ID: 12500852

  • 1. Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.
    Hung AY, Levy L, Kuban DA.
    Cancer J; 2002; 8(6):440-4. PubMed ID: 12500852
    [Abstract] [Full Text] [Related]

  • 2. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2002 Mar 01; 52(3):664-73. PubMed ID: 11849788
    [Abstract] [Full Text] [Related]

  • 3. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 4. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 5. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
    Anderson PR, Hanlon AL, Patchefsky A, Al-Saleem T, Hanks GE.
    Int J Radiat Oncol Biol Phys; 1998 Jul 15; 41(5):1087-92. PubMed ID: 9719119
    [Abstract] [Full Text] [Related]

  • 6. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA, Buchsbaum JC, Elshaikh MA, Reddy CA, Klein EA.
    Int J Radiat Oncol Biol Phys; 2003 Nov 01; 57(3):629-34. PubMed ID: 14529766
    [Abstract] [Full Text] [Related]

  • 7. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA.
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1140-50. PubMed ID: 16198506
    [Abstract] [Full Text] [Related]

  • 8. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.
    Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE.
    Int J Radiat Oncol Biol Phys; 2000 Jul 15; 47(5):1261-6. PubMed ID: 10889379
    [Abstract] [Full Text] [Related]

  • 9. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW, Schild SE, Vora SA, Halyard MY.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):24-9. PubMed ID: 15337536
    [Abstract] [Full Text] [Related]

  • 10. Factors that influence biochemical failure after radiation therapy for stage T1c prostate cancer.
    Mohideen MN, McCall AR, Feinstein J, Sidrys J, Bricker P, Luka S.
    Am J Clin Oncol; 1998 Feb 01; 21(1):6-11. PubMed ID: 9499260
    [Abstract] [Full Text] [Related]

  • 11. Isotope selection for patients undergoing prostate brachytherapy.
    Cha CM, Potters L, Ashley R, Freeman K, Wang XH, Waldbaum R, Leibel S.
    Int J Radiat Oncol Biol Phys; 1999 Sep 01; 45(2):391-5. PubMed ID: 10487561
    [Abstract] [Full Text] [Related]

  • 12. Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995.
    Preston DM, Bauer JJ, Connelly RR, Sawyer T, Halligan J, Leifer ES, McLeod DG, Moul JW.
    Urology; 1999 Jan 01; 53(1):131-8. PubMed ID: 9886602
    [Abstract] [Full Text] [Related]

  • 13. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
    Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2004 Jan 01; 58(1):19-24. PubMed ID: 14697416
    [Abstract] [Full Text] [Related]

  • 14. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.
    Pollack A, Smith LG, von Eschenbach AC.
    Int J Radiat Oncol Biol Phys; 2000 Sep 01; 48(2):507-12. PubMed ID: 10974469
    [Abstract] [Full Text] [Related]

  • 15. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.
    Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL.
    Int J Radiat Oncol Biol Phys; 2003 Nov 15; 57(4):915-28. PubMed ID: 14575822
    [Abstract] [Full Text] [Related]

  • 16. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1003-10. PubMed ID: 15752879
    [Abstract] [Full Text] [Related]

  • 17. Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group.
    Lattanzi JP, Hanlon AL, Hanks GE.
    Int J Radiat Oncol Biol Phys; 1997 Jun 01; 38(3):569-73. PubMed ID: 9231681
    [Abstract] [Full Text] [Related]

  • 18. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA, Katcher J, Levin HS, Klein EA.
    Int J Radiat Oncol Biol Phys; 1997 Mar 15; 37(5):1043-52. PubMed ID: 9169811
    [Abstract] [Full Text] [Related]

  • 19. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy.
    Kestin LL, Goldstein NS, Vicini FA, Martinez AA.
    J Urol; 2002 Nov 15; 168(5):1994-9. PubMed ID: 12394693
    [Abstract] [Full Text] [Related]

  • 20. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E.
    Cancer J Sci Am; 1997 Nov 15; 3(2):78-87. PubMed ID: 9099457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.